- Capital Cube•6 days ago
Hikma Pharmaceuticals Plc relative valuation is now UNDERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 72.Our analysis is based on comparing Hikma Pharmaceuticals Plc with the following peers – Dechra Pharmaceuticals PLC, BTG plc, GlaxoSmithKline plc, GW Pharmaceuticals PLC, AstraZeneca PLC, Summit Therapeutics plc, Sinclair Pharma plc and Vectura Group […] (Read more...) The post Hikma Pharmaceuticals Plc : Undervalued relative to peers, but don’t ignore the other factors appeared first on CapitalCube.
- Reuters•last month
The rush to large-cap, high quality, dividend-paying pharmaceutical stocks in the aftermath of Brexit has helped Europe's healthcare index erase all its losses since last week's vote. The healthcare index, up 1.4 percent on Wednesday, is the only regional sector index to trade above last Thursday's close.
|Bid||2,360.00 x 10900|
|Ask||2,625.00 x 20000|
|52wk Range||1,575.00 - 2,652.00|
|Day's Range||2,598.00 - 2,651.00|
|Avg Vol (3m)||628,332|
As of 12:12 PM EDT. Market closed.